---
title: "Sage Therap | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 31.66 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250854182.md"
datetime: "2025-07-30T20:10:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250854182.md)
  - [en](https://longbridge.com/en/news/250854182.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250854182.md)
generator: "portal-rs"
---

# Sage Therap | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 31.66 M

Revenue: As of FY2025 Q2, the actual value is USD 31.66 M, beating the estimate of USD 16.73 M.

EPS: As of FY2025 Q2, the actual value is USD -0.79, beating the estimate of USD -0.9521.

### Segment Revenue

-   Collaboration revenue from ZURZUVAE was $23.2 million in the second quarter of 2025, representing a 68% increase from the first quarter of 2025 and a significant increase from $7.4 million in the same period in 2024.
-   Other collaboration revenue was $8.5 million in the second quarter of 2025 compared to $0.6 million for the same period in 2024.

### Operational Metrics

-   Cost of revenues was -$0.1 million in the second quarter of 2025, compared to $1.4 million for the same period in 2024.
-   Research and development expenses were $23.7 million in the second quarter of 2025, down from $62.6 million in the same period in 2024.
-   Selling, general and administrative expenses were $62.0 million in the second quarter of 2025, up from $56.0 million in the same period in 2024.
-   Net loss was $49.7 million for the second quarter of 2025 compared to $102.9 million for the same period in 2024.

### Cash Flow

-   Cash, cash equivalents, and marketable securities were $366 million as of June 30, 2025, compared to $424 million at March 31, 2025.

### Unique Metrics

-   Greater than 4,000 prescriptions of ZURZUVAE were shipped to women with postpartum depression in the second quarter of 2025, representing a 36% increase from the first quarter of 2025.

### Outlook / Guidance

-   Sage Therapeutics anticipates significant topline revenue growth in 2025 due to increased commercialization investments for ZURZUVAE.
-   The acquisition by Supernus Pharmaceuticals is expected to close in the third quarter of 2025, with a tender offer of $8.50 per share in cash plus contingent value rights worth up to $3.50 per share.
-   Sage plans to continue exploring its NMDA receptor negative allosteric modulator platform for potential treatments for neurodevelopmental disorders.

### Related Stocks

- [SAGE.US](https://longbridge.com/en/quote/SAGE.US.md)

## Related News & Research

- [Goldman Sachs Keeps Their Hold Rating on Nexi S.p.A. (NEXI)](https://longbridge.com/en/news/297744125.md)
- [Barclays Sticks to Its Buy Rating for Alfa Financial Software plc (ALFA)](https://longbridge.com/en/news/298002731.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**